Technology
Health
Pharmaceutical

Innoviva

$13.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-1.63%) Today
$0.00 (0.00%) As of 4:06 PM EDT after-hours

Why Robinhood?

You can buy or sell Innoviva and other stocks, options, ETFs, and crypto commission-free!

About INVA

Innoviva, Inc. Common Stock, also called Innoviva, is engaged in the development, commercialization, and financial management of bio-pharmaceuticals. Read More Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.

Employees
6
Headquarters
Brisbane, California
Founded
1996
Market Cap
1.43B
Price-Earnings Ratio
3.89
Dividend Yield
0.00
Average Volume
974.15K
High Today
$14.30
Low Today
$13.83
Open Price
$14.04
Volume
1.20M
52 Week High
$20.54
52 Week Low
$13.07

Collections

Technology
Health
Pharmaceutical
Medical
Finance
US
North America

INVA Earnings

$0.31
$0.42
$0.54
$0.65
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 25, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.